Enliven Therapeutics, Inc. (Enliven or the Company) , a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced positive ...
Evidence from multiple model systems supports a shift away from heme transport and toward metabolic dysfunction and oxidative stress as key drivers of TANGO2 deficiency.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback